Table 2.

Demographics of allogeneic HCT recipients

DemographicData
Total 263 
Median follow-up (IQR), mo 16.0 (6.9-30.1) 
Mean age (range), y 60.0 (21.7-78.4) 
HCT-CI  
 0-1  80 (30) 
 2  43 (16) 
 3+  140 (53) 
Conditioning  
 Ablative 173 (66) 
 Reduced or nonmyeloablative 90 (34) 
Diagnosis  
 AML  167 (63) 
 MDS  96 (37) 
HLA match  
 8/8  248 (94) 
 7/8  15 (6) 
GVHD prophylaxis  
 CD34+ selection 121 (46.0) 
 Calcineurin inhibitor based 142 (54.0) 
Refined disease risk index  
 Low/intermediate  142 (54.0) 
 High  91 (34.6) 
 Very high  30 (11.4) 
DemographicData
Total 263 
Median follow-up (IQR), mo 16.0 (6.9-30.1) 
Mean age (range), y 60.0 (21.7-78.4) 
HCT-CI  
 0-1  80 (30) 
 2  43 (16) 
 3+  140 (53) 
Conditioning  
 Ablative 173 (66) 
 Reduced or nonmyeloablative 90 (34) 
Diagnosis  
 AML  167 (63) 
 MDS  96 (37) 
HLA match  
 8/8  248 (94) 
 7/8  15 (6) 
GVHD prophylaxis  
 CD34+ selection 121 (46.0) 
 Calcineurin inhibitor based 142 (54.0) 
Refined disease risk index  
 Low/intermediate  142 (54.0) 
 High  91 (34.6) 
 Very high  30 (11.4) 

Data are number of patients (percentage of total transplant recipients), unless otherwise stated.